Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 17

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 17
---
iamiR Merger. Pursuant to the Merger Agreement, the Company will newly incorporate a wholly owned,
direct subsidiary in the state of Delaware for purposes of consummating the transactions contemplated therein (the “Merger Sub”).
At the closing, subject to terms and conditions of the Merger Agreement, the Merger Sub will merge with and into DiamiR, with DiamiR surviving,
resulting in DiamiR becoming a direct wholly-owned subsidiary of the Company.

Prior to the closing of DiamiR Merger, the Company will transfer by
way of continuation to and domesticate as a Delaware corporation (the “Domestication”; the Company immediately following the
Domestication and prior to the closing of DiamiR Merger, “Aptorum Delaware”). In connection with the Domestication, each then
issued and outstanding Class A ordinary share of the Company will convert automatically, on a one-for-one basis, into a share of common
stock of Aptorum Delaware, each then issued and outstanding Class B ordinary share of the Company will convert automatically, on a one-for-one
basis, into a share of common stock of Aptorum Delaware and a share of non-voting and non-convertible Series A preferred stock of Aptorum
Delaware.

At the closing of DiamiR
Merger, in exchange for all the outstanding common stock of DiamiR, Aptorum Delaware will issue shares of its common stock to
stockholders of DiamiR (excluding the dissenting stockholders to DiamiR Merger), at a pre-determined conversion ratio to the extent
that the stockholders of DiamiR and existing Company shareholders will own approximately 70% and 30%, respectively, of the
outstanding shares of the Combined Company immediately following the closing.

Concurrently with the execution of the Merger Agreement, ATL, a wholly
owned subsidiary of the Company, and DiamiR entered into a management services agreement pursuant to which ATL shall pay a monthly service
fee and reimburse expenses to DiamiR in exchange for the officers and employees of DiamiR providing services to ATL to develop a diagnostic
test for early detection and monitoring of progression of glioblastoma until the earlier of the closing of the Merger or December 31,
2025 in the following positions, subject to change as set forth in the agreement: Alidad Mireskandari, President or CEO; Gary Anthony,
Comptroller or CFO; Gyanendra Kumar, V.P. of Assay